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Abstract
Background: Aortic stiffness is a strong predictor of cardiovascular disease endpoints. Cross-sectional studies have shown
associations of various cardiovascular risk factors with aortic pulse wave velocity, a measure of aortic stiffness, but the long-
term impact of these factors on aortic stiffness is unknown.
Methods: In 3,769 men and women from the Whitehall II cohort, a wide range of traditional and novel cardiovascular risk
factors were determined at baseline (1991–1993) and aortic pulse wave velocity was measured at follow-up (2007–2009).
The prospective associations between each baseline risk factor and aortic pulse wave velocity at follow-up were assessed
through sex stratified linear regression analysis adjusted for relevant confounders. Missing data on baseline determinants
were imputed using the Multivariate Imputation by Chained Equations.
Results: Among men, the strongest predictors were waist circumference, waist-hip ratio, heart rate and interleukin 1
receptor antagonist, and among women, adiponectin, triglycerides, pulse pressure and waist-hip ratio. The impact of
10 centimeter increase in waist circumference on aortic pulse wave velocity was twice as large for men compared with
women (men: 0.40 m/s (95%-CI: 0.24;0.56); women: 0.17 m/s (95%-CI: 20.01;0.35)), whereas the opposite was true for the
impact of a two-fold increase in adiponectin (men: 20.30 m/s (95%-CI: 20.51;20.10); women: 0.61 m/s (95%-CI:
20.86;20.35)).
Conclusion: In this large prospective study, central obesity was a strong predictor of aortic stiffness. Additionally, heart rate
in men and adiponectin in women predicted aortic pulse wave velocity suggesting that strategies to prevent aortic
stiffening should be focused differently by sex.
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Introduction
Aortic pulse wave velocity (aPWV), a measure of aortic stiffness,
is a robust predictor of cardiovascular disease in the general
population and in high risk populations as shown in a recent
metanalysis [1]. This predictive association is independent of
traditional risk factors, such as blood pressure, lipids, and smoking,
and extends over and above the effect of other indicators of arterial
stiffness, such as brachial pulse pressure, central pulse pressure and
carotid-brachial pulse pressure amplification [2]. Thus, aPWV has
been used as an intermediate outcome in several randomized trials
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[3], lipid-lowering treatment [4], and weight loss interventions [5].
The concept that aPWV is both an independent risk factor and
an intermediate marker of cumulated cardiovascular disease risk is
increasingly accepted [6] and is supported by a recent review [7]
of several large-scale studies confirming the cross-sectional
association between cardiovascular risk factors and aPWV.
However, current knowledge is limited on the prospective
association between cardiovascular risk factors and aPWV [8,9].
In the Caerphilly study [9] including men only, heavy smoking, C-
reactive protein (CRP) and pulse pressure were strong predictors
of aPWV 20 years later, but the predictive value of other
biomarkers remains unclear. In cross-sectional studies, central
obesity and inflammation have been strongly associated with
aortic stiffness [10–12]. It is unknown, however, whether waist
circumference and a wide range of inflammatory markers can also
predict aortic stiffness in follow-up examinations. Given the
importance of identifying early determinants of aortic stiffness,
prospective investigations of these associations in men and women
throughout the normal and moderately elevated ranges of
cardiovascular risk factors seem warranted.
In this study from the Whitehall II cohort of British middle-aged
men and women, we sought to examine the extent to which a wide
range of cardiovascular risk factors are associated prospectively
with aPWV.
Methods
Study population
The Whitehall II Study is an occupational cohort including
10,308 British civil servants aged 35–55 at study inception in 1985.
The cohort has been followed with clinical examinations every 5
years and additionally with questionnaires every 2–3 years up to
the end of 2009 (phase 9). Details of the study have been provided
[13]. Only the 9,181 participants of White ethnicity are used in
this study (89%).
The phase 3 examination in 1991–1993 is the baseline for the
present study, as this was the first time a wide range of
cardiovascular risk factors were measured. Measurement of some
of these risk factors was repeated in the 2007–2009 clinical
examination (phase 9) when also the first assessment of aPWV was
performed. A total of 7,955 (87%) participants attended the phase
3 clinical examination. At the phase 9 follow-up examination, 588
(7%) of these had died and another 1,347 (17%) chose not to
participate. Of the 6,020 participants at phase 9, approximately
two thirds had an aPWV measurement. For 60% of participants
with no aPWV measurement, the reason for missing data on
aPWV was station closure due to insufficient staff resources; 5%
had atrial fibrillation and for 20% the carotid or femoral pulse
could not be found. From the 3,894 participants with an aPWV
measurement, we excluded those with previous non-fatal coronary
heart disease at phase 3 (n=81, 2%). To reduce any bias related to
treated diabetes and inflammatory diseases, we further excluded
subjects with known diabetes at phase 3 (n=24, ,1%) and those
reporting use of systemic corticosteroids at any time up to phase 9
(n=20, ,1%), leaving 3,769 participants for analysis.
The University College London ethics committee reviewed and
approved the study, and written informed consent was obtained
from each participant at each examination phase. The study was
conducted according to the principles of the Helsinki Declaration.
Measurements at baseline
The measurements at baseline are described in further details in
the Methods S1. Briefly, height, weight, waist- and hip circum-
ference, blood pressure, and heart rate were measured according
to a standard protocol. Venous blood samples were collected after
an overnight fast in the morning or in the afternoon after no more
than a light fat-free breakfast eaten before 08.00 h. After the initial
venous blood samples were taken, the participants underwent a
standard 2-hour glucose tolerance test. Plasma glucose and serum
insulin were analyzed in both the fasting and 2-hour samples. In
the fasting samples, total cholesterol, high density lipoprotein
(HDL) cholesterol, low density lipoprotein (LDL) cholesterol
(Friedewald equation), triglycerides, apolipoprotein A-I and B,
lipoprotein (a), adiponectin, high sensitive CRP, interleukin 6 (IL-
6), interleukin 1 receptor antagonist (IL-1Ra), fibrinogen, von
Willebrand factor, factor VII activity, and b-carotene were
analyzed.
Information on ethnicity, employment grade, smoking habits,
alcohol consumption and physical activity were collected using a
self-administered questionnaire.
We used the Homeostasis Model Assessment calculator version
2.2 [14] to calculate insulin resistance (HOMA2-IR) and b-cell
function (HOMA2-%B) from the levels of fasting plasma glucose
and fasting serum insulin. Insulin sensitivity was calculated from
fasting- and 2-hour values of plasma glucose and serum insulin
using the insulin sensitivity index (ISI0–120) [15].
Measurements at follow-up
With the participant in a supine position, blood pressure was
measured after 10 minutes of rest. From the supine systolic blood
pressure and diastolic blood pressure, mean arterial pressure was
calculated. The aPWV was then assessed between the carotid and
femoral sites using applanation tonometry (SphygmoCor, Atcor
Medical, Australia), which is a validated method of measuring
aPWV [16]. The path length was determined with a tape measure
by subtracting the carotid-sternal notch distance from the femoral-
sternal notch distance. In each participant, aPWV was measured
twice. If the difference in aPWV between the two measurements
was larger than 0.5 m/s, a third measurement was taken. In the
analyses, the average of the two closest measurements was used. In
125 of the participants, aPWV measurements were repeated
within 60 days to assess the short term reproducibility. The
median intra-individual difference in aPWV was 0.08 m/s
(interquartile range: 20.68 to 0.93 m/s) [17].
Use of antihypertensive-, lipid-lowering-, and glucose-lowering
medication was assessed throughout the follow-up period. We
defined medication history as any known medication up to and
including phase 9 and classified missing information as no known
medication history.
Incident diabetes was assessed throughout the follow-up period
and was based on a standard oral glucose tolerance test at the
clinical examinations (phases 5, 7, and 9) according to the World
Health Organisation definition [18]. Additionally, self-reports of
diabetes or the use of glucose-lowering medication (phases 4, 5, 6,
7, 8 and 9) classified the participants with incident diabetes. The
incidence of non-fatal coronary heart disease was assessed up to
September 2004 [19].
Statistical analysis
The following baseline determinants were considered separately
in the analysis: waist- and hip circumference, waist-hip ratio,
height, diastolic blood pressure, systolic blood pressure, pulse
pressure, heart rate, total cholesterol, HDL cholesterol, LDL
cholesterol, triglycerides, apolipoprotein A-I, apolipoprotein B,
lipoprotein (a), adiponectin, CRP, IL-6, IL-1Ra, fibrinogen, von
Willebrand factor, factor VII, b-carotene, alcohol intake (units/
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hour plasma glucose, HOMA2-%B, HOMA2-IR, and ISI0–120.
Baseline values of plasma glucose and serum insulin for
participants who had been fasting for less than five hours
(n=322, 9%) were assigned as missing data. Prior to analysis,
we removed outliers from all predictors and log-transformed
predictors with a highly skewed distribution (adiponectin, CRP,
IL-6 and IL-1Ra).
For most determinants around five percent or less of the values
were missing. For plasma glucose, serum insulin and the major
part of the inflammatory markers the proportions of missing values
were slightly higher (7–18%). In the study population, a quarter of
the data on b-carotene and half of the data on adiponectin and IL-
1Ra were missing (Table S1). Missing data on baseline determi-
nants were imputed using the Multivariate Imputation by Chained
Equations (MICE) method in R software [20] with missing-at-
random assumptions. Twenty copies of the data [21], each with
missing values suitably imputed, were independently assessed in
the analyses described below. Estimates of parameters of interest
were averaged across the copies to give a single mean estimate.
Standard errors and p-values were adjusted according to Rubin’s
rules [22].
The prospective associations between determinants at baseline
and aPWV at follow-up were assessed through linear regression
analysis stratified by sex and adjusted for mean arterial pressure at
the time of the aPWV measurement [23]. We explored different
levels of adjustment for potential confounders in the analyses; as a
first step we adjusted for age and quadratic age. Secondly, analyses
were additionally adjusted for BMI and lastly we further adjusted
for smoking habits and employment grade as a measure of
socioeconomic status. In all of the analyses of hemodynamic
markers (diastolic blood pressure, systolic blood pressure, pulse
pressure, heart rate) we also adjusted for history of anti-
hypertensive treatment and for incident coronary heart disease.
In the same manner, analyses of lipids (total cholesterol, HDL
cholesterol, LDL cholesterol, triglycerides, apolipoprotein A-I,
apolipoprotein B, lipoprotein (a)) were also adjusted for lipid-
lowering treatment and analyses of indices of glucose metabolism
(fasting plasma glucose, 2-hour plasma glucose, HOMA2-%B,
HOMA2-IR, ISI0–120) were also adjusted for incident diabetes.
Both standardized (per 1 standard deviation difference in the
determinant) and non-standardized regression coefficients are
presented.
A subset of the determinants was also measured at follow-up.
The corresponding cross-sectional associations between these
determinants and aPWV are given in Figure S1 and Table S2.
Analyses were performed using SAS version 9.2 (SAS Institute,
Cary, NC, USA) and R version 2.13.0.
Table 1. Characteristics of the study population at baseline
and at follow-up.
Men Women
N 2,857 912
Baseline
Age (years) 48.4 (5.7) 48.6 (5.9)
BMI (kg/m2) 24.8 (2.9) 24.6 (4.0)
Waist circumference (cm) 87.3 (8.6) 73.8 (10.6)
Hip circumference (cm) 96.6 (5.6) 95.9 (8.5)
Waist-hip ratio 0.90 (0.06) 0.77 (0.06)
Height (cm) 177.0 (6.4) 163.1 (6.2)
Diastolic blood pressure (mmHg) 80.2 (8.8) 75.3 (8.9)
Systolic blood pressure (mmHg) 120.7 (12.5) 115.3 (13.2)
Pulse pressure (mmHg) 40.4 (8.4) 40.0 (8.4)
Heart rate (bpm) 63.0 (10.5) 65.6 (9.8)
Total cholesterol (mmol/l) 6.4 (1.1) 6.3 (1.1)
HDL cholesterol (mmol/l) 1.3 (0.3) 1.7 (0.4)
LDL cholesterol (mmol/l) 4.4 (1.0) 4.1 (1.0)
Triglycerides (mmol/l) 1.5 (0.9) 1.0 (0.6)
Apolipoprotein A–I (mg/dl) 2.1 (0.3) 2.4 (0.4)
Apolipoprotein B (mg/dl) 1.3 (0.3) 1.2 (0.3)
Lipoprotein (a) (mg/dl) 29.9 (29.0) 31.0 (29.6)
Adiponectin (mg/ml) 7.8 (6.0;10.4) 13.1 (9.5;17.4)
CRP (mg/l) 0.7 (0.4;1.4) 0.8 (0.4;1.8)
IL-6 (pg/ml) 1.3 (0.9;1.8) 1.4 (1.0;2.1)
IL-1Ra (pg/ml) 234.9 (187.3;297.7) 259.2 (197.2;353.5)
Fibrinogen (g/l) 2.3 (0.5) 2.5 (0.6)
Von Willebrand factor (IU/dl) 102.3 (36.5) 101.9 (35.2)
Factor VII (% standard) 87.4 (21.6) 89.1 (23.2)
b-carotene (mmol/l) 0.9 (0.5) 1.0 (0.6)
Alcohol intake (units/week) 12.7 (13.6) 6.5 (7.2)
Vigorous exercise (hrs/week) 1.0 (1.6) 0.5 (1.2)
Employment grade (%)
Administrative 44.1 (42.3;45.9) 20.5 (17.9;23.3)
Professional/executive 52.4 (50.5;54.2) 51.1 (47.8;54.4)
Clerical/support 3.5 (2.9;4.3) 28.4 (25.5;31.4)
Smoking habits (%)
Never-smoker 50.3 (48.4;52.1) 55.2 (51.9;58.4)
Ex-smoker 37.2 (35.4;39.0) 28.9 (26.0;32.0)
Current smoker 8.8 (7.8;9.9) 11.8 (9.8;14.1)
Fasting plasma glucose (mmol/l) 5.3 (0.5) 5.0 (0.5)
2-hour plasma glucose (mmol/l) 5.4 (1.7) 5.6 (1.8)
HOMA2-%B (%) 77.8 (26.3) 81.1 (26.6)
HOMA2-IR 0.92 (0.48) 0.88 (0.49)
ISI0,120 45.0 (19.2) 41.5 (16.3)
Follow-up
Aortic pulse wave velocity (m/s) 8.5 (2.0) 8.1 (1.9)
Mean arterial pressure (mmHg) 90.5 (10.3) 86.9 (11.3)
Diabetes incidence (%) 11.4 (10.2;12.6) 10.6 (8.7;12.8)
Non-fatal CHD incidence (%) 5.3 (4.5;6.1) 3.2 (2.1;4.5)
Anti-hypertensive treatment in history
(%)
33.8 (32.0;35.5) 28.7 (25.8;31.8)
Table 1. Cont.
Men Women
Lipid-lowering treatment in history
(%)
31.5 (29.8;33.3) 23.4 (20.6;26.2)
Data are means (SD), medians (interquartile range) or proportions (95% CI)
except for the number of participants (N).
BMI=body mass index; HDL=high density lipoprotein; LDL=low density
lipoprotein; CRP=C-reactive protein; IL-6=interleukin 6; IL-1Ra=interleukin 1
receptor antagonist; HOMA2-%B=b-cell function; HOMA2-IR=insulin
resistance; ISI0–120=insulin sensitivity index; CHD=coronary heart disease.
doi:10.1371/journal.pone.0037165.t001
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Participants were mainly men (76%). Women had lower blood
pressure levels and fewer coronary heart disease events than men.
Women had a more favorable lipid profile, and a lower proportion
of women were on lipid-lowering or anti-hypertensive treatment
(Table 1). Median follow-up time was 16.3 years (range: 13.1–
17.6). Participants lost to follow-up and phase 9 participants with
no aPWV measurement were more likely to be women, to be
smokers and to be in lower employment grade, they were older
and slightly more obese and with higher levels of low-grade
inflammation compared to the study participants. This was in
particular true for those lost to follow-up (Table S3).
Central obesity (waist circumference and waist-hip ratio) was a
strong predictor of aPWV 16 years later in both sexes, even after
adjustment for BMI (Figure 1). Systolic blood pressure, heart rate,
HDL cholesterol, triglycerides, apolipoprotein B, adiponectin,
CRP, IL-1Ra, and fibrinogen were also significantly associated
with aPWV in both sexes. Among men, waist circumference was
the strongest determinant of aPWV at follow-up whereas among
women triglycerides and adiponectin had the strongest association
with aPWV (Figure 1).
For most determinants, adjustment for BMI slightly attenuated
the association with aPWV in men, while the BMI adjustment had
no effect in women. Indicators of central obesity remained strong
predictors of aPWV and for both sexes waist circumference
became a slightly stronger determinant for aPWV when adjusting
for BMI (Figure 1). Further adjustment for employment grade and
smoking habits had very little effect over adjustment for BMI and
are therefore not shown.
The associations corresponding to the model adjusting for BMI
are reported on the original scale of the determinants in Table 2.
The impact of waist circumference on aPWV was twice as large
for men compared with women, whereas the opposite was true for
triglycerides and adiponectin. The effect of heart rate was almost
Figure 1. Standardized regression coefficients for predicting aortic pulse wave velocity. Light blue: adjustment for age, quadratic age,
mean arterial pressure at the time of aortic pulse wave velocity measurement, and for relevant treatment and event history. Dark blue: further
adjustment for body mass index. HDL=high density lipoprotein; LDL=low density lipoprotein; CRP=C-reactive protein; IL-6=interleukin 6; IL-
1Ra=interleukin 1 receptor antagonist; HOMA2-%B=b-cell function; HOMA2-IR=insulin resistance; ISI0–120=insulin sensitivity index.
doi:10.1371/journal.pone.0037165.g001
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predictor of aPWV among women only.
Corresponding associations between risk factors and aPWV
were seen in the cross-sectional analysis except that the
associations with most of the indicators of glucose metabolism
were stronger cross-sectionally, while the association with
adiponectin was weaker. The absolute impact of heart rate on
Table 2. Difference (95%-CI) in aortic pulse wave velocity at follow-up by a unit difference in baseline determinants.
Determinants Men Women
Anthropometrics
Waist circumference (10 cm) 0.40 (0.24;0.56)
{ 0.17 (20.01;0.35)*
Hip circumference (10 cm) 20.04 (20.23;0.14) 20.06 (20.26;0.15)
Waist-hip ratio 4.12 (2.60;5.64)
{ 2.63 (0.60;4.65)
{
Height (10 cm) 0.06 (20.04;0.16) 20.06 (20.23;0.11)
Hemodynamic markers
Diastolic blood pressure (10 mmHg) 0.11 (0.03;0.20)
{ 0.00 (20.14;0.14)
Systolic blood pressure (10 mmHg) 0.05 (0.00;0.11)* 0.14 (0.04;0.23)
{
Pulse pressure (10 mmHg)
I 0.00 (20.08;0.08) 0.26 (0.12;0.39)
{
Heart rate (10 bpm)
I 0.30 (0.24;0.37)
{ 0.13 (0.02;0.24)*
Lipids
Total cholesterol (mmol/l) 0.04 (20.02;0.10) 0.08 (20.02;0.19)
HDL cholesterol (mmol/l) 20.38 (20.58;20.17)
{ 20.28 (20.55;20.02)*
LDL cholesterol (mmol/l) 0.03 (20.04;0.10) 0.11 (20.01;0.23)*
Triglycerides (mmol/l) 0.18 (0.10;0.25)
{ 0.30 (0.10;0.50)
{
Apolipoprotein A–I (mg/dl) 20.22 (20.43;20.01)* 0.02 (20.28;0.32)
Apolipoprotein B (mg/dl) 0.36 (0.11;0.60)
{ 0.60 (0.16;1.03)
{
Lipoprotein (a) (10 mg/dl) 0.01 (20.02;0.03) 0.03 (20.01;0.07)
Inflammatory markers
Adiponectin (two-fold increase) 20.30 (20.51;20.10)
{ 20.61 (20.86;20.35)
{
CRP (two-fold increase) 0.13 (0.07;0.19)
{ 0.14 (0.04;0.25)
{
IL-6 (two-fold increase) 0.28 (0.15;0.40)
{ 0.23 (0.02;0.43)
IL-1Ra (two-fold increase) 0.46 (0.22;0.70)
{ 0.42 (0.08;0.75)
{
Fibrinogen (g/l) 0.33 (0.19;0.48)
{ 0.24 (0.04;0.44)
Von Willebrand factor (10 IU/dl) 0.01 (0.00;0.03) 0.00 (20.04;0.03)
Factor VII (10% standard) 0.05 (0.02;0.09)
{ 0.01 (20.04;0.06)
Lifestyle
b-carotene (mmol/l) 20.13 (20.31;0.05) 0.08 (20.13;0.30)
Alcohol intake (10 units/week) 0.08 (0.03;0.12)
{ 20.03 (20.18;0.11)
Vigorous exercise (hrs/week) 20.09 (20.13;20.05)
{ 20.10 (20.19;20.01)*
Ex-smoker vs. never smoker 20.01 (20.14;0.13) 20.09 (20.33;0.14)
Current smoker vs. never smoker 0.15 (20.08;0.38) 20.06 (20.39;0.26)
Glucose metabolism
Fasting plasma glucose (mmol/l) 0.21 (0.07;0.34)
{ 0.17 (20.05;0.39)
2-hour plasma glucose (mmol/l) 0.05 (0.01;0.09)
{ 0.02 (20.04;0.09)
HOMA2-%B (100 units) 0.20 (20.08;0.48) 0.01 (20.52;0.53)
HOMA2-IR 0.19 (0.01;0.37)* 0.12 (20.20;0.44)
ISI0,120 (100 units) 20.35 (20.69;20.02)* 20.16 (20.83;0.52)
Analyses were adjusted for age, quadratic age, BMI, mean arterial pressure at the time of aortic pulse wave velocity measurement, relevant treatment and events
(Hemodynamic markers: anti-hypertensive treatment and coronary heart disease events; lipids: lipid-lowering treatment; glucose metabolism: diabetes incidence).
*P,0.05,
{P,0.01,
{P,0.0001 for significance of the determinant.
1P,0.05,
IP,0.01 for sex difference in the determinant.
BMI=body mass index; HDL=high density lipoprotein; LDL=low density lipoprotein; CRP=C-reactive protein; IL-6=interleukin 6; IL-1Ra=interleukin 1 receptor
antagonist; HOMA2-%B=b-cell function; HOMA2-IR=insulin resistance; ISI0–120=insulin sensitivity index; CHD=coronary heart disease.
doi:10.1371/journal.pone.0037165.t002
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women (Figure S1 and Table S2).
Discussion
In this study of 3,769 men and women of White ethnicity, we
found that several traditional cardiovascular risk factors as well as
indicators of low-grade inflammation were associated with aortic
stiffness 16 years later, and that the pattern of associations differed
by sex. The strongest determinants of aortic stiffness, in order of
magnitude, were waist circumference, waist-hip ratio, heart rate
and IL-1Ra among men, and adiponectin, triglycerides, pulse
pressure and waist-hip ratio among women.
To our knowledge this is the first study to examine the long term
effect of traditional and novel cardiovascular risk factors on aortic
stiffness in both men and women. In our study, central obesity and
low-grade inflammation were strong predictors of aortic stiffness in
both sexes. A marked difference between sexes was observed in the
impact of triglycerides and adiponectin, which was twice as high in
women, and in heart rate which was almost three times as high in
men than in women.
Our findings among men are broadly in line with those from the
Caerphilly study [9] on 825 Welsh men during 20 years of follow-
up. However, there were differences in the ranking of the
determinants between the two studies, as low-grade inflammation
was one of the strongest determinants of aortic stiffness and had a
much larger impact than central obesity on aortic stiffness in the
Caerphilly study. These differences may be attributable to the
lower mean age and healthier risk profile of the men in the
Whitehall II cohort and may also reflect the difference in level of
adjustment in the analyses. Both studies adjusted for age and mean
arterial pressure. We additionally adjusted for quadratic age, BMI
and medication- and event history where relevant, whereas the
Caerphilly study instead adjusted for heart rate and medication at
time of follow-up only.
The observed sex differences in the relative importance of long-
term determinants of aortic stiffness are important as it may point
to differences in the etiology of cardiovascular disease between
men and women. These findings also hold possible clues for how
preventive strategies might be targeted differently by sex. It is,
however, important to note that in the occupational Whitehall II
cohort lower employment grades are overrepresented among
women compared to men. This key indicator of socioeconomic
status [24] has shown to be strongly related to cardiovascular risk
factors and general health in this cohort [13]. Although we found
no confounding effect of employment grade in our analyses, we
cannot fully discount the role of the sex specific socio-economic
structure in the Whitehall II population.
Determinants of aortic stiffness
Central obesity and inflammation. Waist circumference
and waist-hip ratio were among the strongest predictors of aortic
stiffness among men and women, but with somewhat higher effect
in men. The association with waist circumference was strength-
ened upon adjustment for BMI indicating that central obesity is
the main contributing factor to the association between obesity
and aortic stiffness. Our findings are in accordance with a cross-
sectional study measuring visceral fat by computer tomography in
2,488 men and women. The study found that besides systolic
blood pressure, visceral fat had the strongest independent
association with aPWV [11]. The importance of fat accumulation
as a determinant of aortic stiffness was further highlighted by our
findings of a strong negative association between adiponectin and
aortic stiffness in both sexes. Results from cross-sectional studies
are all in line with our results [25,26].
We also found other markers of low-grade inflammation, such
as CRP, IL-6, IL-1Ra and fibrinogen to predict aortic stiffness in
both sexes. Factor VII were additionally associated with aortic
stiffness in men. These findings are in line with the Caerphilly
study, which found an association of CRP and fibrinogen with
aortic stiffness in men [9] and several cross-sectional studies
reporting a strong association between CRP and aPWV [10,12].
There are only few studies on the association between IL-6, IL-
1Ra, fibrinogen, von Willebrand factor and factor VII and aPWV,
and the results are inconsistent [10,27,28].
Although the association between inflammation and aortic
stiffness may merely reflect the inflammatory burden caused by
aortic stiffness or its determinants, an experimental study showed
that acute systemic inflammation induced by vaccination with
Salmonella typhi increases aPWV [29], supporting the hypothesis
that inflammation is actually on the causal pathway leading to
aortic stiffness. A further study supports this concept by showing
that aortic stiffness is increased in people with rheumatoid arthritis,
and that stiffness may be reversed by immunomodulatory therapy
[30].
Lipids. Dyslipidaemia is an important, well-established and
modifiable cardiovascular risk factor. However, apolipoprotein A–
I and apolipoprotein B may have an even stronger effect on
coronary heart disease [31]. We are the first to study the impact of
a detailed lipid profile on aortic stiffness and found that HDL
cholesterol and apolipoprotein B were associated with aortic
stiffness in both sexes but with higher absolute and relative
magnitude of apolipoprotein B in women (Table 2 and Figure 1).
Additionally, LDL cholesterol in women and apolipoprotein A–I
in men were to a lesser degree associated with aortic stiffness.
We found triglycerides to have a robust association with aortic
stiffness in both sexes, but with an association twice as strong in
women compared to men. This striking sex difference is also
supported by a meta-analysis on incident coronary heart disease
[32]. The mechanisms behind this sex difference are poorly
understood but may be a result of sex-specific differences in lipid
metabolism. Our findings are in line with the findings of the
Framingham Offspring Study, which identified apolipoprotein B
and HDL cholesterol as major determinants of incident coronary
heart disease [33].
Glucose metabolism. Few studies exist on the long term
effect of markers of glucose metabolism on aortic stiffness. In our
study, the magnitude of the association between glucose metab-
olism and aortic stiffness after 16 years was comparable to that of
inflammation and blood pressure in men but smaller than that of
triglycerides and obesity. We found no association with aPWV in
women. The Caerphilly study measured fasting plasma glucose as
a marker of glucose metabolism but found no association with
aortic stiffness.
Heart rate and blood pressure. There were also marked
sex differences in the association between heart rate and pulse
pressure and aortic stiffness. The association with heart rate was
almost three times higher in men as in women, whereas pulse
pressure was significantly associated with aortic stiffness in women
only. The findings in the Caerphilly study on heart rate and pulse
pressure are not in agreement with our results in men, which could
be explained by the Whitehall II cohort being younger and thus
pulse pressure may be a less accurate reflection of aortic stiffness.
Alcohol. The association between alcohol consumption and
aortic stiffness differed by sex. Among men, we found a statistically
significantly positive association with aortic stiffness. In women,
however, the association was negative, although not statistically
Long Term Determinants of Aortic Stiffness
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social class, as the alcohol intake was markedly larger among
highly educated women than among women with no education,
whereas the difference in alcohol consumption across education
level among men was less pronounced [34].
Strengths and limitations
This study included middle-aged British civil servants of White
ethnicity limiting the generalizability of our results. Due to the lack
of a baseline measure of aPWV, we cannot conclude on causality.
Clinical trials targeting the identified risk factors for aortic stiffness
are needed to assess causality. A tape measure was used to
determine the carotid-femoral path length which may have
overestimated the distance in obese individuals resulting in an
overestimated aPWV.
For most of the determinants 5% or more were missing. Instead
of complete case analysis, we have used multiple imputation to
handle the large number of missing data in this study. Several
simulation studies have shown that complete case analysis
generally leads to biased estimates, but that multiple imputation
reduces this bias and increases precision [35,36]. MICE is
currently the state-of-the-art-method of dealing with data missing
at random [37].
Of the 7,955 participants attending the phase 3 examination,
3,894 had measurements of aPWV at follow-up. We cannot
exclude bias due to the healthy survivor effect, which might have
weakened the associations, but the ranking of the determinants
should not be affected by this effect.
We cannot fully conclude on whether the found associations are
truly predictive or merely an effect of the risk tracking over time.
We have adjusted the analyses for medication history, incident
diabetes and coronary heart disease to account for temporal
instability in the predictor variables that was outside the natural
course of ageing, and the ranking and strength of the associations
were largely replicated in the cross-sectional analyses. However,
future studies assessing the trajectories of risk factors up to the time
of aortic stiffness measurement would enable a more precise
quantification of the impact of the risk factors over time.
In conclusion, this large prospective study of middle-aged men
and women found central obesity and low-grade inflammation to
be strong predictors of aPWV in both sexes. In addition, heart rate
in men and adiponectin and triglycerides in women were strongly
associated with aPWV suggesting that prevention strategies
targeting aortic stiffness should focus on central obesity and heart
rate among men and triglycerides and central obesity among
women.
Supporting Information
Figure S1 Standardized cross-sectional regression coef-
ficients for association with aortic pulse wave velocity.
(DOC)
Methods S1 Detailed information on baseline measure-
ments.
(DOC)
Table S1 The fraction of the study participants with no
information on the baseline determinant.
(DOC)
Table S2 Difference (95%-CI) in aortic pulse wave
velocity at follow-up by a unit difference in determinants
at follow-up.
(DOC)
Table S3 Baseline characteristics by follow-up partici-
pation and aortic pulse wave velocity measurement for
those alive at follow-up.
(DOC)
Acknowledgments
We thank Maren Carstensen, Ulrike Poschen and Karin Ro ¨hrig (all from
the German Diabetes Center) for the IL-6 and adiponectin measurements.
Author Contributions
Conceived and designed the experiments: NBJ DV EJB AGT MJS MK
DRW CMM IBW. Performed the experiments: CH DRW AGT. Analyzed
the data: DV NBJ DRW MK MS EJB AGT CMM IBW. Contributed
reagents/materials/analysis tools: CMM IBW. Wrote the paper: NBJ DV.
Made critical revision of the manuscript for important intellectual content:
MK MS MR CH DRW EJB AGT CMM IBW.
References
1. Vlachopoulos C, Aznaouridis K, Stefanadis C (2010) Prediction of cardiovas-
cular events and all-cause mortality with arterial stiffness: a systematic review
and meta-analysis. J Am Coll Cardiol 55: 1318–1327.
2. Mitchell GF, Hwang SJ, Vasan RS, Larson MG, Pencina MJ, et al. (2010)
Arterial stiffness and cardiovascular events: the Framingham Heart Study.
Circulation 121: 505–511.
3. Boutouyrie P, Achouba A, Trunet P, Laurent S, EXPLORE Trialist Group
(2010) Amlodipine-valsartan combination decreases central systolic blood
pressure more effectively than the amlodipine-atenolol combination: the
EXPLOR study. Hypertension 55: 1314–1322.
4. Ichihara A, Hayashi M, Koura Y, Tada Y, Kaneshiro Y, et al. (2005) Long-term
effects of statins on arterial pressure and stiffness of hypertensives. J Hum
Hypertens 19: 103–109.
5. Dengo AL, Dennis EA, Orr JS, Marinik EL, Ehrlich E, et al. (2010) Arterial
destiffening with weight loss in overweight and obese middle-aged and older
adults. Hypertension 55: 855–861.
6. Laurent S, Cockcroft J, Van-Bortel L, Boutouyrie P, Giannattasio C, et al.
(2006) Expert consensus document on arterial stiffness: methodological issues
and clinical applications. Eur Heart J 27: 2588–2605.
7. Cecelja M, Chowienczyk P (2009) Dissociation of aortic pulse wave velocity with
risk factors for cardiovascular disease other than hypertension: a systematic
review. Hypertension 54: 1328–1336.
8. Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, et al. (2002)
Determinants of accelerated progression of arterial stiffness in normotensive
subjects and in treated hypertensive subjects over a 6-year period. Circulation
105: 1202–1207.
9. McEniery CM, Spratt M, Munnery M, Yarnell J, Lowe GD, et al. (2010) An
analysis of prospective risk factors for aortic stiffness in men: 20-year follow-up
from the Caerphilly prospective study. Hypertension 56: 36–43.
10. Lieb W, Larson MG, Benjamin EJ, Yin X, Tofler GH, et al. (2009) Multimarker
approach to evaluate correlates of vascular stiffness: the Framingham Heart
Study. Circulation 119: 37–43.
11. Sutton-Tyrrell K, Newman A, Simonsick EM, Havlik R, Pahor M, et al. (2001)
Aortic stiffness is associated with visceral adiposity in older adults enrolled in the
study of health, aging, and body composition. Hypertension 38: 429–433.
12. Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, et al. (2004) C-
reactive protein is associated with arterial stiffness in apparently healthy
individuals. Arterioscler Thromb Vasc Biol 24: 969–974.
13. Marmot M, Brunner E (2005) Cohort Profile: the Whitehall II study.
Int J Epidemiol 34: 251–256.
14. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA
modeling. Diabetes care 27: 1487–1495.
15. Gutt M, Davis CL, Spitzer SB, Llabre MM, Kumar M, et al. (2000) Validation
of the insulin sensitivity index (ISI(0,120)): comparison with other measures.
Diabetes Research and Clinical Practice 47: 177–184.
16. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, et al. (1998)
Reproducibility of pulse wave velocity and augmentation index measured by
pulse wave analysis. J Hypertens 16: 2079–2084.
17. Brunner EJ, Shipley MJ, Witte DR, Singh-Manoux A, Britton AR, et al. (2011)
Arterial stiffness, physical function, and functional limitation: the Whitehall II
Study. Hypertension 57: 1003–1009.
18. World Health Organisation (1999) Definition, Diagnosis and Classification of
Diabetes Mellitus and its Complications.
Long Term Determinants of Aortic Stiffness
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e3716519. Virtanen M, Ferrie JE, Singh-Manoux A, Shipley MJ, Vahtera J, et al. (2010)
Overtime work and incident coronary heart disease: the Whitehall II prospective
cohort study. Eur Heart J 31: 1737–1744.
20. van-Buuren S (2007) Multiple imputation of discrete and continuous data by
fully conditional specification. Stat Methods Med Res 16: 219–242.
21. Graham JW, Olchowski AE, Gilreath TD (2007) How many imputations are
really needed? Some practical clarifications of multiple imputation theory. Prev
Sci 8: 206–213.
22. Rubin DB (1987) Multiple imputation for nonresponse in surveys. New York:
Wiley.
23. London GM, Pannier B (2010) Arterial functions: how to interpret the complex
physiology. Nephrol Dial Transplant 25: 3815–3823.
24. Marmot MG, Smith GD, Stansfeld S, Patel C, North F, et al. (1991) Health
inequalities among British civil servants: the Whitehall II study. Lancet 337:
1387–1393.
25. Windham BG, Griswold ME, Farasat SM, Ling SM, Carlson O, et al. (2010)
Influence of leptin, adiponectin, and resistin on the association between
abdominal adiposity and arterial stiffness. Am J Hypertens 23: 501–507.
26. Holewijn S, den-Heijer M, van-Tits LJ, Swinkels DW, Stalenhoef AF, et al.
(2010) Impact of waist circumference versus adiponectin level on subclinical
atherosclerosis: a cross-sectional analysis in a sample from the general
population. J Intern Med 267: 588–598.
27. Schnabel R, Larson MG, Dupuis J, Lunetta KL, Lipinska I, et al. (2008)
Relations of inflammatory biomarkers and common genetic variants with
arterial stiffness and wave reflection. Hypertension 51: 1651–1657.
28. Sie MP, Isaacs A, de-Maat MP, Mattace-Raso FU, Uitterlinden AG, et al.
(2009) Genetic variation in the fibrinogen-alpha and fibrinogen-gamma genes in
relation to arterial stiffness: the Rotterdam Study. J Hypertens 27: 1392–1398.
29. Vlachopoulos C, Dima I, Aznaouridis K, Vasiliadou C, Ioakeimidis N, et al.
(2005) Acute systemic inflammation increases arterial stiffness and decreases
wave reflections in healthy individuals. Circulation 112: 2193–2200.
30. Ma ¨ki-Peta ¨ja ¨ KM, Hall FC, Booth AD, Wallace SM, Yasmin, et al. (2006)
Rheumatoid arthritis is associated with increased aortic pulse-wave velocity,
which is reduced by anti-tumor necrosis factor-alpha therapy. Circulation 114:
1185–1192.
31. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, et al. (2001) High
apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of
fatal myocardial infarction (AMORIS study): a prospective study. Lancet 358:
2026–2033.
32. Hokanson JE, Austin MA (1996) Plasma triglyceride level is a risk factor for
cardiovascular disease independent of high-density lipoprotein cholesterol level:
a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3:
213–219.
33. Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, et al. (2007)
Clinical utility of different lipid measures for prediction of coronary heart disease
in men and women. JAMA 298: 776–785.
34. Britton A, Marmot M (2004) Different measures of alcohol consumption and risk
of coronary heart disease and all-cause mortality: 11-year follow-up of the
Whitehall II Cohort Study. Addiction 99: 109–116.
35. White IR, Carlin JB (2010) Bias and efficiency of multiple imputation compared
with complete-case analysis for missing covariate values. Stat Med 29:
2920–2931.
36. Janssen KJ, Donders AR, Harrell FE, Vergouwe Y, Chen Q, et al. (2010)
Missing covariate data in medical research: to impute is better than to ignore.
J Clin Epidemiol 63: 721–727.
37. Sterne JA, White IR, Carlin JB, Spratt M, Royston P, et al. (2009) Multiple
imputation for missing data in epidemiological and clinical research: potential
and pitfalls. BMJ 338: b2393.
Long Term Determinants of Aortic Stiffness
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e37165